RR31 Antibody

What is the RR31 antibody and what epitopes does it recognize?

The RR31 antibody (clone R31) is a mouse monoclonal IgG1 antibody that specifically recognizes an epitope present on the nucleocapsid protein of Hantavirus strain R22, also known as the Seoul (SEO) serotype . This antibody was developed using the nucleocapsid protein of Hantavirus R22 strain as the immunogen and is primarily applied in diagnostic and research applications for Hantavirus detection .

The specificity of RR31 is significant because Hantaviruses are negative-sense RNA viruses in the Bunyaviridae family that can cause potentially fatal diseases in humans, including Hantavirus hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) . The antibody's ability to detect specific viral proteins makes it valuable for laboratory investigations of viral pathogenesis.

How does RR31 antibody compare with other antibodies used in Hantavirus research?

RR31 antibody offers specific advantages in Hantavirus research compared to other available antibodies:

The RR31 antibody's specificity for the Seoul serotype makes it particularly valuable for epidemiological studies in regions where this serotype is prevalent . Its ability to function in multiple applications (ELISA, IF, IHC) provides researchers with flexibility in experimental design.

What are the optimal protocols for using RR31 antibody in immunohistochemistry (IHC)?

When using RR31 antibody for IHC applications, researchers should follow these methodological considerations:

• Tissue preparation: Formalin-fixed, paraffin-embedded tissues require appropriate antigen retrieval methods to expose the nucleocapsid protein epitope. Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is generally recommended.

• Dilution optimization: Begin with 1:100 dilution of hybridoma culture supernatant and optimize based on signal-to-noise ratio for your specific tissue type.

• Detection systems: For mouse monoclonal antibodies like RR31, use secondary antibody detection systems that minimize cross-reactivity with endogenous immunoglobulins, particularly when analyzing rodent tissues.

• Controls: Include appropriate positive controls (known Hantavirus-infected tissues) and negative controls (isotype-matched irrelevant antibody) to validate specificity.

• Visualization: DAB (3,3'-diaminobenzidine) chromogen is commonly used for visualization, with hematoxylin counterstaining to provide tissue context.

The antibody's successful application in IHC enables researchers to study the tissue distribution of Hantavirus antigens, which is crucial for understanding viral pathogenesis in different host species .

How can I optimize ELISA protocols using RR31 antibody for Hantavirus detection?

For optimal ELISA performance using RR31 antibody:

• Coating conditions: Coat ELISA plates with recombinant nucleocapsid protein or viral lysate (1-10 μg/mL) in carbonate-bicarbonate buffer (pH 9.6) overnight at 4°C.

• Blocking: Use 3-5% BSA or non-fat dry milk in PBS-T (PBS with 0.05% Tween-20) for 1-2 hours at room temperature to reduce background.

• Antibody incubation: Apply RR31 antibody at optimized dilution (typically starting at 1:500) in blocking buffer for 1-2 hours at room temperature or overnight at 4°C.

• Detection system: Use HRP-conjugated anti-mouse IgG secondary antibody followed by TMB substrate for colorimetric detection.

• Validation: Include a standard curve using purified nucleocapsid protein to enable quantitative analysis.

This methodology enables sensitive detection of Hantavirus antigens in various sample types, including serum, tissue homogenates, or environmental samples, with applications in both research and diagnostic settings .

What is the relationship between RAB31 antibodies and disease progression in clinical research?

RAB31, also known as RAB22B, is a small GTPase of the RAB family that plays crucial roles in vesicular trafficking and has emerged as an important factor in disease progression . Research findings indicate:

• Cancer progression: RAB31 expression levels correlate with negative prognoses for colorectal cancer patients, as demonstrated in multiple online meta-databases . Forest plots reveal that RAB31 expression is associated with a high risk ratio in colorectal cancer cohorts, comparable to other significant prognostic variables .

• Chemotherapy resistance: RAB31 significantly alters sensitivity to oxaliplatin, a supplementary chemotherapy approach for colorectal cancer. Gene expression analysis identified RAB31 as one of 18 candidate genes upregulated in oxaliplatin-resistant colorectal cancer cell lines .

• Epithelial-mesenchymal transition (EMT): RAB31 expression levels positively correlate with EMT scores. Overexpression of RAB31 suppresses the epithelial-type marker CDH1 while increasing expression of mesenchymal-type markers SNAI1 and SNAI2 .

• Extracellular vesicle secretion: RAB31-induced EMT and drug resistance depend on extracellular vesicle secretion. The RAB31/AGR2 axis-mediated exocytosis maintains colorectal cell resistance to oxaliplatin .

These findings position RAB31 as an independent prognostic factor in certain cancers and suggest that antibodies targeting RAB31 may have potential therapeutic applications.

What experimental methods are most effective for studying RAB31's role in vesicular trafficking?

To effectively study RAB31's role in vesicular trafficking, researchers should consider these methodological approaches:

• Immunofluorescence and confocal microscopy: Using anti-RAB31 antibodies (such as the rabbit polyclonal antibody ab230881) for co-localization studies with markers of different vesicular compartments (early endosomes, trans-Golgi network, etc.) .

• Live-cell imaging: Employing fluorescently tagged RAB31 constructs to track vesicle movement in real-time, particularly useful for studying the dynamics of vesicular trafficking.

• Biochemical fractionation: Isolating different vesicular compartments through differential centrifugation followed by immunoblotting with anti-RAB31 antibodies to determine the subcellular distribution of RAB31.

• GTPase activity assays: Measuring the GTP-binding and hydrolysis activities of RAB31 to understand its cycling between active (GTP-bound) and inactive (GDP-bound) forms.

• Proximity ligation assays: Identifying RAB31 interaction partners in vesicular trafficking pathways, particularly valuable for discovering novel effectors.

Research has demonstrated that RAB31 is required for the integrity and normal function of the Golgi apparatus and trans-Golgi network, and plays roles in insulin-stimulated GLUT4 translocation, M6PR transport, EGFR internalization, and phagosome maturation .

How does RAB31 deficiency impact megakaryocytic vesicle trafficking and what methodological approaches best demonstrate this?

Research investigating RAB31 deficiency in megakaryocytic vesicle trafficking has revealed significant impacts on protein trafficking mechanisms. Studies demonstrate that:

• Decreased RAB31 expression in RHD: Platelet expression profiling using Affymetrix U133 Gene Chips revealed decreased RAB31 expression in patients with RUNX1 mutations (fold change: 0.28775, p = 0.008) . This was validated by real-time PCR and immunoblotting, which confirmed reduced platelet RAB31 in patients with RHD compared to healthy subjects .

• RUNX1 regulation of RAB31: Electrophoretic mobility shift assays using infrared-labeled RAB31 probes identified four RUNX1 consensus sites in the RAB31 promoter region (-2013/-1 from ATG) . Binding reactions between nuclear extract and probe, followed by supershift assays with anti-RUNX1 antibody, demonstrated direct regulation of RAB31 by RUNX1 .

Methodological approaches that best demonstrate RAB31's impact include:

• Transmission electron microscopy to visualize ultrastructural changes in megakaryocytic granules and vesicles

• Live-cell imaging with fluorescent RAB31 constructs to track vesicle dynamics in real-time

• Proteomic analysis of vesicle contents to identify proteins affected by RAB31 deficiency

• Knock-down/knock-out models combined with rescue experiments to establish causality

These approaches provide compelling evidence that RAB31 regulates megakaryocytic vesicle trafficking of major proteins with diverse biological functions .

What are the critical considerations when designing antibody-based therapeutic approaches targeting RAB31 in cancer?

When designing antibody-based therapeutic approaches targeting RAB31 in cancer, researchers should consider:

• Cellular localization challenges: RAB31 primarily localizes to intracellular vesicular compartments, making it less accessible to conventional antibody therapeutics. Researchers must develop strategies for intracellular delivery, such as antibody-drug conjugates, cell-penetrating peptides, or nanoparticle-based delivery systems.

• Specificity within the RAB family: The RAB family contains numerous members with high sequence homology. Antibody therapeutics must demonstrate exquisite specificity for RAB31 to avoid off-target effects on other RAB GTPases that may have contradictory functions in cancer progression.

• GTP/GDP-bound state selectivity: RAB31, like other small GTPases, cycles between active (GTP-bound) and inactive (GDP-bound) conformations. Therapeutic antibodies should ideally target the active conformation or interfere with the GTP/GDP cycling mechanism to effectively inhibit RAB31 function.

• Validation in multiple cancer models: Research has shown that RAB31 plays context-dependent roles in different cancer types. Therapeutic approaches should be validated across multiple cancer models to determine optimal applications .

• Combination therapy potential: Given RAB31's involvement in chemotherapy resistance, particularly to oxaliplatin in colorectal cancer, antibody therapeutics targeting RAB31 might be most effective when combined with conventional chemotherapeutics .

These considerations are crucial for developing effective antibody-based interventions that could overcome treatment resistance and improve patient outcomes.

What are the optimal methods for evaluating neutralizing antibody responses in experimental models?

Evaluating neutralizing antibody responses requires methodological rigor, particularly in experimental vaccination models. Key approaches include:

• Plaque reduction neutralization tests (PRNT): The gold standard for determining protection against viruses like measles. While ELISA is often used as a proxy (detecting antibodies at approximately 200mIU/mL), PRNT more accurately measures functional neutralizing capacity .

• Sequential immunization strategies: Studies of HIV neutralizing antibody development demonstrate that sequential immunization with modified antigens can engage precursor antibodies and drive affinity maturation toward broadly neutralizing antibodies. In mouse models expressing human IGHV1-2(*02) segments, sequential immunization with modified gp120 glycoproteins enabled the development of HIV-neutralizing antibody lineages .

• Combined humoral and cellular immunity assessment: Comprehensive evaluation should measure both antibody titers and T-cell responses, as a study of measles revaccination in HIV-infected children demonstrated that durable antibody responses corresponded to lower T-cell activation and anergy .

• Long-term follow-up: To assess the durability of neutralizing responses, testing should be conducted at multiple time points after immunization (e.g., 1 month, 12 months, and 24 months post-vaccination), as seen in measles revaccination studies where seropositivity decreased from 98% at one month to 60% at 24 months .

• Correlation with viral suppression: In subjects with viral infections like HIV, neutralizing antibody responses correlate with viral suppression. Among children with plasma HIV RNA <50 copies/mL, 39% measles seroconverted compared with only 4% of children with HIV RNA ≥1,000 copies/mL (p=0.018) .

These methodological approaches provide more robust assessment of neutralizing antibody responses than simple binding assays alone.

How should researchers interpret conflicting antibody test results in experimental settings?

When faced with conflicting antibody test results, researchers should implement this systematic approach:

• Consider test methodology differences: Different assays have varying sensitivities and specificities. For example, ELISA may detect antibodies at approximately 200mIU/mL, while plaque reduction neutralization tests (PRN) can detect lower levels of functional antibodies . Compare methodological details including:

  • Detection limits

  • Antigen presentation formats

  • Secondary detection systems

  • Signal amplification methods

• Evaluate antibody isotype and subclass detection: Some assays may preferentially detect certain antibody isotypes or subclasses. IgG4, for instance, may be underrepresented in assays optimized for IgG1 detection.

• Assess timing of sample collection: Antibody kinetics vary significantly over time. For example, in measles revaccination studies, seropositivity rates were 98% at one month but decreased to 60% by 24 months post-revaccination .

• Consider host factors affecting antibody responses: In immuno-compromised subjects, antibody production and maintenance may be impaired. Among HIV-infected children, for instance, plasma HIV RNA levels significantly impacted measles seroconversion rates .

• Implement tiered testing strategies: Begin with screening assays (e.g., ELISA) followed by confirmatory tests (e.g., neutralization assays) for discrepant results.

• Evaluate antibody functionality: Beyond simple binding, assess whether antibodies perform their intended biological functions through appropriate functional assays.

This systematic approach ensures more accurate interpretation of contradictory results and guides appropriate experimental or clinical decision-making.

What are the current standards for validating antibody specificity in research applications?

Validation of antibody specificity requires comprehensive approaches to ensure experimental reliability:

• Multi-technique validation: Antibody specificity should be confirmed using at least two independent techniques (e.g., Western blot, immunohistochemistry, immunoprecipitation, flow cytometry). Each technique provides different information about binding characteristics.

• Appropriate controls: Critical controls include:

  • Positive controls (samples known to express the target)

  • Negative controls (samples known not to express the target)

  • Isotype controls (irrelevant antibodies of the same isotype)

  • Genetic knockout/knockdown validation (CRISPR-Cas9 or siRNA)

  • Peptide competition assays (pre-absorption with immunizing peptide)

• Cross-reactivity assessment: Testing against related family members is essential, particularly for targets within large protein families. For RAB31 antibodies, cross-reactivity with other RAB family members should be thoroughly evaluated .

• Application-specific validation: Antibodies must be validated separately for each application (WB, IHC, ICC/IF) and species, as demonstrated by the RAB31 antibody (ab230881) validation for human, rat, and mouse samples across multiple applications .

• Reporting standards: Adherence to guidelines such as those proposed by the International Working Group for Antibody Validation (IWGAV) ensures transparent reporting of validation methods and results.

Following these validation standards ensures experimental reproducibility and reliable interpretation of results, which is particularly crucial for research on complex targets like RAB31 or viral epitopes recognized by RR31 antibody.

How do regulatory frameworks differ for research-grade versus diagnostic antibodies?

The regulatory frameworks governing research-grade versus diagnostic antibodies exhibit significant differences that impact their development, validation, and application:

For researchers working with RR31 antibody or RAB31 antibodies, understanding these distinctions is crucial when transitioning from research applications to potential diagnostic or therapeutic applications. The Anti-Hantavirus Seoul Serotype Monoclonal Antibody (R31 clone) would require extensive additional validation and manufacturing controls if repurposed from research applications to diagnostic use in Hantavirus detection .

Additionally, researchers should note that IHC applications using antibodies in diagnostic pathology face particularly stringent requirements for reproducibility and clinical correlation compared to research applications of the same antibodies.

How might advances in antibody engineering enhance the utility of RR31 or RAB31-targeting antibodies?

Advanced antibody engineering technologies offer several promising avenues to enhance the utility of RR31 or RAB31-targeting antibodies:

• Bispecific antibody formats: Engineering bispecific antibodies that simultaneously target RR31's epitope on Hantavirus nucleocapsid protein and a second viral or cellular target could enhance diagnostic sensitivity or therapeutic efficacy. Similarly, bispecific antibodies targeting RAB31 and associated trafficking proteins could provide more specific modulation of vesicular trafficking pathways.

• Intracellular antibody delivery systems: Since RAB31 functions primarily within intracellular compartments, developing antibody delivery systems using cell-penetrating peptides, nanoparticle formulations, or mRNA-encoded antibodies could overcome the limited access of conventional antibodies to intracellular targets.

• Antibody-drug conjugates (ADCs): For cancer applications targeting RAB31-overexpressing tumors, ADCs could selectively deliver cytotoxic payloads to cancer cells while sparing normal tissues. This approach could be particularly valuable given RAB31's role in oxaliplatin resistance in colorectal cancer .

• Single-domain antibodies (nanobodies): These smaller antibody fragments derived from camelid antibodies offer advantages for accessing restricted epitopes and improved tissue penetration, potentially enhancing both diagnostic and therapeutic applications targeting RAB31.

• Conformation-specific antibodies: Developing antibodies that specifically recognize the active (GTP-bound) form of RAB31 would enable more precise modulation of its activity, particularly in cancer contexts where RAB31 activation drives disease progression.

These engineering approaches could significantly expand the research and clinical applications of antibodies targeting RR31 epitopes or RAB31, providing more specific and effective tools for both diagnostic and therapeutic purposes.

What role might artificial intelligence play in optimizing antibody-based research on Hantavirus or RAB31-associated diseases?

Artificial intelligence approaches are revolutionizing antibody-based research with several key applications for Hantavirus or RAB31-associated diseases:

• Epitope prediction and antibody design: AI algorithms can predict immunogenic epitopes on Hantavirus nucleocapsid proteins that might be recognized by antibodies like RR31, enabling the design of more effective diagnostic antibodies or vaccines. Similarly, for RAB31, AI can identify unique epitopes that distinguish it from other RAB family members.

• Patient stratification and biomarker identification: Machine learning analysis of multi-omics data can identify patient subgroups most likely to respond to RAB31-targeted therapies based on expression patterns and pathway activation. For example, colorectal cancer patients with high RAB31 expression and oxaliplatin resistance might benefit from specific therapeutic approaches .

• Image analysis in antibody-based diagnostics: Deep learning algorithms can enhance the analysis of immunohistochemistry or immunofluorescence images, improving the sensitivity and specificity of RAB31 detection in cancer tissues or Hantavirus detection in infected samples.

• Molecular dynamics simulations: AI-enhanced simulations can model antibody-antigen interactions at atomic resolution, predicting binding affinities and optimizing antibody structures for improved recognition of Hantavirus epitopes or RAB31 conformational states.

• High-throughput experimental design and analysis: AI can design optimal antibody screening strategies and analyze complex experimental data to accelerate the discovery of antibodies with desired properties for both research and clinical applications.

These AI approaches promise to significantly accelerate research progress and translate discoveries into clinically relevant applications for both infectious diseases like Hantavirus and cancer pathways involving RAB31.